Neurocrine Biosciences Total Cash From Operating Activities History
| NBIX Stock | USD 160.45 4.65 2.98% |
Total Cash From Operating Activities | First Reported 1996-03-31 | Previous Quarter 388.4 million | Current Value 145.8 million | Quarterly Volatility 70.45 million |
Macro event markers
Latest Neurocrine Biosciences Total Cash From Operating Activities Growth Pattern
| Total Cash From Operating Activities | 10 Years Trend |
|
Total Cash From Operating Activities |
| Timeline |
Total Cash From Operating Activities Trend Statistics
Measured across 15 periods, Neurocrine Biosciences' Total Cash From Operating Activities has a coefficient of variation of 153.6% (wide dispersion driven primarily by directional growth rather than instability). The regression fit of 0.77 reflects a strong linear fit indicating consistent directional movement.| Arithmetic Mean | 195,181,588 | |
| Coefficient Of Variation | 153.60 | |
| Mean Deviation | 240,936,927 | |
| Median | 101,400,000 | |
| Standard Deviation | 299,793,665 | |
| Sample Variance | 89876.2T | |
| Range | 928M | |
| R-Value | 0.88 | |
| Mean Square Error | 22243.5T | |
| R-Squared | 0.77 | |
| Slope | 52,026,738 | |
| Total Sum of Squares | 1438019.9T |
Neurocrine Biosciences Total Cash From Operating Activities History
Reported values for Neurocrine Biosciences' Total Cash From Operating Activities span 2012 to 2026 (15 observations), ranging from -35.29 million to 821.84 million.Correlation of Total Cash From Operating Activities With Other Accounts
Linear correlations between Total Cash From Operating Activities and other accounts within Neurocrine Biosciences' reporting history are shown below. Strong correlations may reflect underlying operational relationships or scaling effects across related metrics.Click cells to compare fundamentals
Related Fundamentals
| Last Reported | End Of Year Estimate | ||
| Other Cashflows From Financing Activities | $-38.3 million | $-36.38 million | |
| Total Cash From Financing Activities | $-38.3 million | $-36.38 million | |
| Total Cashflows From Investing Activities | $-264.4 million | $-251.18 million | |
| Change To Operating Activities | $-15.48 million | $-14.71 million |
Methodology, Assumptions & Data Sources
Historical trajectory of Neurocrine Biosciences's Total Cash From Operating Activities across available reporting periods. The regression slope and R-squared together indicate whether the directional trend is persistent or episodic. Neurocrine Biosciences' Total Cash From Operating Activities is best evaluated in the context of Biotechnology sector operating characteristics.
Neurocrine Biosciences figures are aggregated from periodic company reporting and market reference feeds and normalized across reporting formats. Professional analyst research is incorporated when coverage is available. Reference data and historical patterns are presented and do not constitute an investment recommendation or advice.
Editorial review and methodology oversight provided by: Michael Smolkin, Member of Macroaxis Board of Directors